Oncotelic Therapeutics Merges AI and Robotics in Pharma Automation Push

Oncotelic Therapeutics (OTCQB: OTLC) is making headlines with a strategic pivot that merges its clinical-stage biopharmaceutical expertise with cutting-edge artificial intelligence and industrial automation. The company, known for its focus on oncology and immunotherapy, has announced a partnership with TechForce Robotics to commercialize an AI-enhanced platform designed for regulated pharmaceutical environments. This collaboration leverages Oncotelic’s proprietary PDAOAI platform, an AI-driven system aimed at improving compliance, monitoring, and operational intelligence. By integrating this innovation with TechForce Robotics’ hardware and manufacturing capabilities, the companies aim to deliver a GMP-compliant robotics solution that automates critical workflows in pharmaceutical production and laboratory settings. The news was featured in a recent article, which highlighted this strategic move beyond Oncotelic’s traditional roots into the rapidly expanding intersection of AI and automation.

Oncotelic Therapeutics continues to advance its core mission of addressing high-unmet-need cancers and rare pediatric indications through innovative therapeutic candidates. The company’s drug pipeline is bolstered by the extensive patent portfolio of its CEO, Dr. Vuong Trieu, who holds 39 issued U.S. patents and has filed over 150 patent applications. Beyond its internal programs, Oncotelic owns 45% of GMP Bio, a joint venture that is advancing complementary drug candidates under Trieu’s leadership. This partnership with TechForce Robotics represents a diversification strategy that could position Oncotelic at the forefront of AI-driven pharmaceutical automation, potentially enhancing its value proposition for investors and stakeholders.

Investors seeking the latest updates on OTLC can find news in the company’s newsroom at https://nnw.fm/OTLC. The announcement was disseminated by NetworkNewsWire, a financial news platform that is part of the Dynamic Brand Portfolio within IBN. NetworkNewsWire provides a range of corporate communications solutions, including press release distribution and social media amplification, to help companies reach a broad audience. This coverage underscores the growing interest in how biotechnology firms are leveraging AI to improve operational efficiency and regulatory compliance.